Dr. Praveen Kandi is currently working as Director of Drug Product Development, CMC & Preclinical at Bristol Myers Squibb Company. Dr. Kandi is a passionate, accomplished and well recognized expert and leader in drug development for numerous generic ANDAs and several NDAs from early stage product and process development to late stage validation/ commercialization. Treatment of numerous debilitating ailments in CNS disorders , Epilepsy, Cancer, etc. Dr. Kandi was the drug product lead on the recently approved medication for Schizophrenia treatment: KarXT - COBENFY NDA Approved, https://www.cobenfy.com, which was voted in TIME magazine as one of the best inventions in 2024. Dr. Kandi currently holds master degree in molecular genetics and biochemistry from Georgia State University and a PHD in Pharmaceutical sciences from Mercer University, Atlanta, G.A, and Leadership Certification from Harvard. With 20+years of industrial experience working for small, mid, and large size Pharmaceutical/Biotechnology company’s and 11+ years of advanced research experience in various aspects of drug development, being a leader in product and process development. Dr. Kandi brings a wealth of knowledge & proven expertise in various dosage forms (solid, liquid, semisolid, and sterile products), drug delivery technologies, and analytical methods. Dr. Kandi passion is to create innovative solutions for poorly soluble drugs, such as cocrystals, lipid-based, and polymeric systems, that enhance their bioavailability, efficacy, and safety.

Formulation, Process and Product Dev., Scale-up, Technology Transfer,  Validation, Analytical, Drug Delivery, Small Molecules, Poorly Soluble Drugs, NDAs, ANDAs, Regulatory Drug Product SME, Finance & Budgets, CDMOs, Contract Negotiations, Patents, Problem solving, Results-oriented, Leadership (People & Teams) and Project Management Skills, Change management & Continuous improvement.